It’s no secret that cancer treatment has become its own thriving industry and the money to be made from prescribing cutting edge pharmaceuticals, chemotherapy and radiation “treatment” is immense.
Profit is the paradigm for modern medicine, but as our knowledge of cancer continues to grow we continue to be reminded that many verifiable effective and affordable treatments for cancer exist, but seems to be unwanted or outright prohibited by the medical establishment.
Mebendazole (MBZ) is a commonly found, over-the-counter anti-parasite medication, used most often to rid the body of pinworms. It came into use in 1971, and now retails under a number of product names including Vermox, Ovex, Antiox, Combantrin and Pripsen.
Found in most pharmacies and even available online, the drug is widely used, yet very few are aware of the effect it is seen to have in fighting cancerous tumors.
In the fight against cancer, the main attempt is to isolate then attack specific cells with poisons or by surgically removing body tissue. Radiation and chemotherapy are dangerous to the entire body, killing much more than just cancerous growths.
MBZ, on the other hand is a unique treatment because it does not seek to kill cancerous cells with poisons, targeting instead the reproductive process of cells that have been replicating beyond their natural limit.
Known as micri-tubule inhibitors, this class of drugs prevents the replication of cells who’ve overgrown their capacity to reproduce correctly, which is the very nature of cancer.
“Human cells have a maximum number of times that they can reproduce themselves before the accumulated errors finally prevent reproduction — it’s called the Hayflick Limit. Most scientists agree that this number is around 60 times.
“This ‘programmed’ lifespan of a cell is determined by the length of a benign string of molecules attached to the ends of the DNA coils. Like leaders on a movie film, these break off or become misaligned during the replication process and provide a buffer zone, protecting the real DNA code. The longer a cell’s leader, called a telomere, the more it can reproduce and the longer an organism can live.” [Source]
First synthesized in the late 1960’s subsequent research has revealed more about the drug’s potency in stopping cancer cells without causing collateral damage.
A 2014 study entitled, “Repurposing Drugs in Oncology (ReDO) — mebendazole as an anti-cancer agent,” concluded MBZ holds great promise in treating tumors, especially when used in combination with other existing cancer treatments.
“Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types…
“Based on the evidence presented, it is proposed that mebendazole would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted.” [Source]
Taken orally as a chewable tablet or in liquid form, the medicine has appeared in a number of cancer studies, including this study that looked at the effects of MBZ on cancerous tumors of the lungs:
“Oral administration of MZ in mice elicited a strong antitumor effect in a s.c. model and reduced lung colonies in experimentally induced lung metastasis without any toxicity when compared with paclitaxel-treated mice.” [Source]
The last manufacturer of mebendazole in the United States was Teva pharmaceuticals who for unstated reasons discontinued the product in 2011, however, foreign-sourced brands are available for sale in pharmacies and at Amazon.com in the US — click here.
It is not yet recognized by the medical establishment as an anti-cancer drug, however, it many physicians are able to recommend its usage for reasons other than treating worms.
Add mebendazole to the growing list of so-called ‘alternative’ cancer treatments which are affordable, effective, widely available, yet broadly ignored by the cancer industry.
By Alex Pietrowski, Waking Times | References:
http://viewzone.com; https://en.wikipedia.org; http://www.ncbi.nlm.nih.gov; http://www.ncbi.nlm.nih.gov; http://neuro-oncology.oxfordjournals.org